Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for VTE Prevention in Glioma Patients with Postoperative Dyskinesia
NCT06196918Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Nov 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in venous thromboembolism (VTE) comparing Rivaroxaban group with Placebo group (2 arms). Primary endpoint: Venous thromboembolism at 6 months. Started Nov 2023; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06196918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196918.